$COR — Provides critical care medical products and services.

$COR — Provides critical care medical products and services. 🎯 Q1 FY26 | Rev $78B | EPS $4.75 vs $4.73 🟢 | Margin 1.6% 💡 Consensus expects steady but unexciting EPS growth (~7% YoY) from Cencora, driven by modest revenue gains and margin stability. The market may be underestimating the potential for operating leverage from cost controls and the recent guidance raise (adjusted EPS raised to $4.75 vs prior $4.60–$4.70). 🏢 Business Quality: 7/10 | Valuation: fair 📉 Reward/Risk: Upside 8% to $306 (16.5x FY26 EPS of $18.55) vs downside 12% to $250 (13.5x FY26 EPS). Ratio ~0.67:1, unfavorable at current price. 🔮 Catalyst: Next quarterly report (fiscal Q3, expected Aug 2026). Metric to watch: adjusted EPS vs raised guidance midpoint of $4.75. Also in play: $OXY $DVN $MRO $APA $CTRA $HAL

🎯 Q1 FY26 | Rev $78B | EPS $4.75 vs $4.73 🟢 | Margin 1.6%